• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

葡萄糖转运蛋白1/3/4作为人类乳腺癌预后的新型生物标志物

GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer.

作者信息

Zeng Kai, Ju Gaoda, Wang Hao, Huang Jiangsheng

机构信息

Department of Minimally Invasive Surgery, the Second Xiangya Hospital, Central South University, Changsha 410000, China.

Yancheng TCM Hospital, Nanjing University of Chinese Medicine, Yancheng 224002, China.

出版信息

Transl Cancer Res. 2020 Apr;9(4):2363-2377. doi: 10.21037/tcr.2020.03.50.

DOI:10.21037/tcr.2020.03.50
PMID:35117597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8797933/
Abstract

BACKGROUND

Anomalous expression of glucose transporters (GLUTs) has been observed in a variety of tumor tissues. Although GLUT factors have been shown to have prognostic value for some cancer types, detailed bioinformatics investigation of the factors contributing to the prognostic prediction for patients with breast cancer (BC) has not yet been performed.

METHODS

In this study, we examined the transcription levels of , , and and their associations with prognostic clinical data in patients with BC from the ONCOMINE database, using gene expression profiling interactive analysis (GEPIA), Kaplan-Meier (KM) plotter, and cBioPortal online tools.

RESULTS

The transcription level of was significantly higher in the BC samples than in the normal tissues, whereas the levels of and were lower in the BC samples. The expression levels of and were associated with the cancer clinical stage. Consistently, survival analysis demonstrated that a high expression level of was associated with low relapse-free survival (RFS) in patients with BC, whereas high and levels predicted a longer RFS in these patients.

CONCLUSIONS

Overall, these results suggest as an effective target of precision therapy, while are novel biomarkers for the prognosis of patients with BC.

摘要

背景

在多种肿瘤组织中均观察到葡萄糖转运蛋白（GLUTs）的异常表达。尽管已表明GLUT因子对某些癌症类型具有预后价值，但尚未对影响乳腺癌（BC）患者预后预测的因素进行详细的生物信息学研究。

方法

在本研究中，我们使用基因表达谱交互式分析（GEPIA）、Kaplan-Meier（KM）绘图仪和cBioPortal在线工具，从ONCOMINE数据库中检查了BC患者中、和的转录水平及其与预后临床数据的关联。

结果

BC样本中的转录水平显著高于正常组织，而BC样本中的和水平较低。和的表达水平与癌症临床分期相关。同样，生存分析表明，高表达水平与BC患者的无复发生存期（RFS）低相关，而高和水平预测这些患者的RFS更长。

结论

总体而言，这些结果表明是精准治疗的有效靶点，而和是BC患者预后的新型生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2b21bc5a727c/tcr-09-04-2363-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2592d847681e/tcr-09-04-2363-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/d01db321ed02/tcr-09-04-2363-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/dcce14721830/tcr-09-04-2363-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/c223e1159b29/tcr-09-04-2363-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/e1bf11f3ace8/tcr-09-04-2363-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/ec7afe4f30fd/tcr-09-04-2363-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/3a6398409099/tcr-09-04-2363-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2a61977ed5d5/tcr-09-04-2363-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/33524a1b2bf4/tcr-09-04-2363-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2b21bc5a727c/tcr-09-04-2363-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2592d847681e/tcr-09-04-2363-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/d01db321ed02/tcr-09-04-2363-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/dcce14721830/tcr-09-04-2363-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/c223e1159b29/tcr-09-04-2363-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/e1bf11f3ace8/tcr-09-04-2363-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/ec7afe4f30fd/tcr-09-04-2363-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/3a6398409099/tcr-09-04-2363-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2a61977ed5d5/tcr-09-04-2363-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/33524a1b2bf4/tcr-09-04-2363-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d128/8797933/2b21bc5a727c/tcr-09-04-2363-f10.jpg

相似文献

1
GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer.葡萄糖转运蛋白1/3/4作为人类乳腺癌预后的新型生物标志物
Transl Cancer Res. 2020 Apr;9(4):2363-2377. doi: 10.21037/tcr.2020.03.50.
2
Glucose transporters GLUT1, GLUT3, and GLUT4 have different effects on osteoblast proliferation and metabolism.葡萄糖转运蛋白GLUT1、GLUT3和GLUT4对成骨细胞的增殖和代谢有不同影响。
Front Physiol. 2022 Nov 29;13:1035516. doi: 10.3389/fphys.2022.1035516. eCollection 2022.
3
The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma.转录因子STAT3是一个潜在靶点，而转录因子STAT5A/5B/6是人类乳腺癌预后的新生物标志物。
Oncotarget. 2017 May 30;8(22):36279-36288. doi: 10.18632/oncotarget.16748.
4
Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis.转录因子 c-Jun 调节糖酵解过程中的 GLUT1 并影响乳腺癌转移。
BMC Cancer. 2022 Dec 7;22(1):1283. doi: 10.1186/s12885-022-10393-x.
5
Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer.溶质载体-谷氨酰胺转运蛋白在乳腺癌中作用的生物信息学分析
Ann Transl Med. 2022 Jul;10(14):777. doi: 10.21037/atm-22-2620.
6
Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis.葡萄糖转运蛋白在上皮性卵巢癌中的表达：与临床特征及肿瘤血管生成的相关性
Oncol Rep. 2007 Aug;18(2):361-7.
7
CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.CMTM5/7 是人类乳腺癌的生物标志物和预后因素。
Cancer Biomark. 2020;29(1):89-99. doi: 10.3233/CBM-191226.
8
Expressions and prognostic values of the transcription factors in human breast carcinoma.转录因子在人乳腺癌中的表达及其预后价值
Cancer Manag Res. 2018 Sep 13;10:3521-3532. doi: 10.2147/CMAR.S172332. eCollection 2018.
9
Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.雌激素受体 1 和孕激素受体是雌激素受体阳性乳腺癌的独特生物标志物和预后因素：来自生物信息学分析的证据。
Biomed Pharmacother. 2020 Jan;121:109647. doi: 10.1016/j.biopha.2019.109647. Epub 2019 Nov 13.
10
Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis.运用综合生物信息学分析鉴定乳腺肿瘤微环境中CXC趋化因子的潜在治疗靶点
Cell Physiol Biochem. 2018;45(5):1731-1746. doi: 10.1159/000487782. Epub 2018 Feb 23.

引用本文的文献

1
Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation.骨桥蛋白：肿瘤进展和免疫调节中的关键多面调节因子。
Biomedicines. 2024 Jul 9;12(7):1527. doi: 10.3390/biomedicines12071527.
2
The Molecular Mechanisms behind Advanced Breast Cancer Metabolism: Warburg Effect, OXPHOS, and Calcium.晚期乳腺癌代谢的分子机制：瓦博格效应、OXPHOS 和钙。
Front Biosci (Landmark Ed). 2024 Mar 13;29(3):99. doi: 10.31083/j.fbl2903099.
3
Prognostic value of glucose transporter proteins-1 (GLUT1) in breast carcinoma.葡萄糖转运蛋白-1（GLUT1）在乳腺癌中的预后价值。

本文引用的文献

1
Glucose transporter 1 in health and disease.健康与疾病中的葡萄糖转运蛋白1
J Oral Maxillofac Pathol. 2019 Sep-Dec;23(3):443-449. doi: 10.4103/jomfp.JOMFP_22_18.
2
Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer.mTOR 信号通路分子在三阴性乳腺癌中的表达。
Pathobiology. 2019;86(5-6):315-321. doi: 10.1159/000503311. Epub 2019 Nov 8.
3
Breast cancer statistics, 2019.乳腺癌统计数据，2019 年。
Libyan J Med. 2023 Dec;18(1):2283953. doi: 10.1080/19932820.2023.2283953. Epub 2023 Nov 21.
4
Analysis of the relationship between GLUT family in the progression and immune infiltration of head and neck squamous carcinoma.分析 GLUT 家族与头颈部鳞状细胞癌进展和免疫浸润的关系。
Diagn Pathol. 2023 Aug 4;18(1):88. doi: 10.1186/s13000-023-01377-x.
5
Progesterone Receptor-Mediated Regulation of Cellular Glucose and F-Fluorodeoxyglucose Uptake in Breast Cancer.孕激素受体介导的乳腺癌细胞葡萄糖及F-氟脱氧葡萄糖摄取的调控
J Endocr Soc. 2022 Dec 3;7(2):bvac186. doi: 10.1210/jendso/bvac186. eCollection 2022 Dec 15.
6
Design and Characterization of Maltoheptaose--Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen.麦芽七糖-聚苯乙烯纳米粒的设计与表征，作为一种潜在的新型口服纳米载体用于他莫昔芬传递。
Molecules. 2021 Oct 28;26(21):6507. doi: 10.3390/molecules26216507.
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.
4
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy.癌细胞中的 Glut1 以及白藜芦醇的抑制作用——一种有潜力的治疗策略。
Int J Mol Sci. 2019 Jul 9;20(13):3374. doi: 10.3390/ijms20133374.
5
Analysis of miRNA-mRNA network reveals miR-140-5p as a suppressor of breast cancer glycolysis via targeting GLUT1.miRNA-mRNA 网络分析揭示 miR-140-5p 通过靶向 GLUT1 抑制乳腺癌糖酵解。
Epigenomics. 2019 Jul;11(9):1021-1036. doi: 10.2217/epi-2019-0072. Epub 2019 Jun 11.
6
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.血浆游离 DNA 基因组检测观察到 TP53、EGFR 和 PIK3CA 基因变异，这些变异是乳腺癌和肺癌的重要生物标志物。
J Biotechnol. 2019 Jul 20;300:87-93. doi: 10.1016/j.jbiotec.2019.05.005. Epub 2019 May 14.
7
New approach for understanding genome variations in KEGG.KEGG 中基因组变异的新方法。
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595. doi: 10.1093/nar/gky962.
8
Glucose transporters in cancer - from tumor cells to the tumor microenvironment.癌症中的葡萄糖转运蛋白——从肿瘤细胞到肿瘤微环境。
FEBS J. 2018 Aug;285(16):2926-2943. doi: 10.1111/febs.14577. Epub 2018 Jun 25.
9
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.MAP3K1 和 MAP2K4 突变与多种癌症模型中对 MEK 抑制剂的敏感性相关。
Cell Res. 2018 Jul;28(7):719-729. doi: 10.1038/s41422-018-0044-4. Epub 2018 May 24.
10
GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress.GLUT1 可保护前列腺癌细胞免受葡萄糖剥夺诱导的氧化应激。
Redox Biol. 2018 Jul;17:112-127. doi: 10.1016/j.redox.2018.03.017. Epub 2018 Apr 12.